

in collaboration with the
Cancer Biomarker Research Group
at the National Cancer Institute

Early Detection of Pancreatic Cancer: Opportunities and Challenges in Utilizing Electronic Health Records (eHR)

MONDAY, MARCH 29, 2021 • 1:00 - 5:00 PM (EDT)



Limor Appelbaum, M.D.
Staff Scientist, Department of Radiation Oncology
BETH ISRAEL DEACONESS MEDICAL CENTER (BIDMC)
Instructor, HARVARD MEDICAL SCHOOL

WORKSHOP TOPIC: Development and Validation of a Pancreatic Cancer Prediction Model

using the TriNetX Global Research Network

Limor Appelbaum, M.D., is a Staff Scientist in the Department of Radiation Oncology, Beth Israel Deaconess Medical Center (BIDMC), and Instructor at Harvard Medical School. Dr. Appelbaum's research

focuses on developing and validating risk prediction models for pancreatic cancer using electronic health record data, in collaboration with Prof. Martin Rinard's group from MIT Computer Science and Artificial Intelligence Laboratory (CSAIL). Her preliminary model, developed on BIDMC data, and validated on Partners Healthcare data, was published in the *European Journal of Cancer*. Current work, in collaboration with TriNetx, a global health research network company, focuses on utilizing a multi-national medical records database, to improve performance of the preliminary model. Dr. Appelbaum's goal is to develop a model that can be clinically implemented to identify individuals at high risk for developing pancreatic cancer, from the general population, early enough to allow curative treatment.

She received her M.D. from Semmelweis University in Budapest, Hungary, and completed her Internship year at Soroka University Medical Center, Israel. She completed her Radiation Oncology residency at Hadassah Hebrew University Medical Center, and then served as a Senior Radiation Oncologist before coming to Boston.

Contact Information:

lappelb1@bidmc.harvard.edu